Gilead Sciences announced that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company in early 2025. Dr. Parsey will continue in his role while the company searches for a successor and assist with the transition through Q1 2025 or as mutually agreed.During his five-year tenure since November 2019, Dr. Parsey has led significant expansion of the development organization, overseeing global clinical development and medical affairs. Under his leadership, the company more than doubled its portfolio and currently maintains 54 ongoing clinical trials across virology, oncology, and inflammation.CEO Daniel O'Day praised Parsey's fundamental role in strengthening and diversifying the company's portfolio during pivotal years. Parsey's achievements include advancing market-leading treatments in virology and establishing Gilead's oncology pipeline and therapeutics, positioning the company for continued success in delivering transformative medicines.

Gilead Sciences announced that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company in early 2025. Dr. Parsey will continue in his role while the company searches for a successor and assist with the transition through Q1 2025 or as mutually agreed.During his five-year tenure since November 2019, Dr. Parsey has led significant expansion of the development organization, overseeing global clinical development and medical affairs. Under his leadership, the company more than doubled its portfolio and currently maintains 54 ongoing clinical trials across virology, oncology, and inflammation.CEO Daniel O'Day praised Parsey's fundamental role in strengthening and diversifying the company's portfolio during pivotal years. Parsey's achievements include advancing market-leading treatments in virology and establishing Gilead's oncology pipeline and therapeutics, positioning the company for continued success in delivering transformative medicines.